Registered patients increase 43% during quarter to over 16,500, and over 21,000 today
SMITHS FALLS, ON, Aug. 29, 2016 /CNW/ - Canopy Growth Corporation (TSX:CGC) ("Canopy Growth" or "the Corporation") today released its financial results for the first quarter fiscal 2017 ended June 30, 2016. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.
Consolidated financial results include the accounts of the Company and its wholly‑owned subsidiaries Tweed Inc. ("Tweed"), Tweed Farms Inc. ("Tweed Farms") and Bedrocan Canada Inc. ("Bedrocan Canada").
First Quarter Fiscal 2017 Highlights
Subsequent to First Quarter Fiscal 2017
"Our business took many important steps forward, in both Canada and abroad, during the first quarter," said Bruce Linton, Chairman & CEO, Canopy Growth. "Continued investment helped our business deliver its eighth consecutive quarter of double digit percentage growth in revenue, product sold and registered patients. During the quarter we brought the full Tweed Farms greenhouse, all 350,000 square feet, into production. With close to 600,000 sq. ft. in production across the corporation, in both low cost greenhouse and indoor growing facilities, the capability and flexibility that we have to produce large quantities of high quality dried cannabis and extracts, to meet potential future market demand, is unmatched in the sector."
Added Linton "Investment in international development drove agreements with partners in Australia, Brazil, and Germany. With other opportunities presenting themselves, the global expansion of our business has just begun."
First Quarter Fiscal 2017 Revenue Review
Revenue for the fourth quarter was $7.0 million compared to revenue of $1.7 million in the three months ended June 30, 2015 and $5.0 million for the fourth quarter of fiscal year 2016.
First Quarter Fiscal 2017 Product Sales Review
In the first quarter of fiscal 2017 ended June 30, 2016, the Company sold approximately 984 kilograms and kilogram equivalents at an average price of $7.09 per gram. In the three-month period ended June 30, 2015, approximately 215 kilograms were sold at an average price of $7.74 per gram. The impact of Bedrocan's True Compassionate Pricing program, introduced in the fourth quarter of fiscal 2016, reduced the average selling price per gram.
First Quarter Fiscal 2017 Gross Margin Review
The gross margin was $3.4 million, or 49% of revenue, for the three month period ended June 30, 2016. In the comparative period last year, the gross margin on the same basis was $4.1 million or 239% of revenue.
First Quarter Fiscal 2017 Adjusted Product Contribution Review
The Company's "Adjusted Product Contribution"1 is a Non-GAAP metric used by management which adjusts the reported gross margin by excluding the fair value measurements as required by IFRS and measures the cost of sales for the grams actually sold in the period. Management believes this measure provides useful information as it reflects the gross margin based on the Company's weighted average cost per gram from seed to sale against the grams sold.
The Adjusted Product Contribution in the first quarter of fiscal 2017 was $4.4 million, or 63% of revenue. In the comparative period last year, the Adjusted Product Contribution was $1.0 million, or 60% of revenue.
First Quarter Fiscal 2017 Operating Expense Review
For the three months ended June 30, 2016, sales and marketing expenses were $2.3 million, or 32% of revenue (three months ended June 30, 2015 - $1.0 million, or 59% of revenue).
The increase in sales and marketing expenses in the three months ended June 30, 2016 over the comparison period was due to expansion of the customer care center, launching Tweed's customer engagement locations, an expanded medical outreach program and continuing to position the Tweed brand in preparation for a non-medical market.
General and Administrative ("G&A") expenses were $2.9 million, or 41% of revenue, in the three-month period ended June 30, 2016 compared to $1.4 million, or 83% of revenue, in the same period last year.
The increase in G&A expenses over the comparison period last year reflects the Company's growth over last year, building commercial capacity and capability as a public company and meeting compliance requirements with Health Canada.
First Quarter Fiscal 2017 Earnings Review
The Company reported a net loss of $3.9 million or $0.04 per basic and diluted share for the first quarter ended June 30, 2016, compared to net income of $1.0 million or $0.02 per basic and diluted share in the comparison period last year. The net loss was inclusive of the non-cash unrealized gain on changes in fair value of biological assets described above. The non-cash gain on biological assets more than offset other cost of sales and operating expenses in the first quarter of last year to produce positive net income.
First Quarter Fiscal 2017 Balance Sheet and Cash Flow Review
At June 30, 2016, the Corporation's cash, comprised of cash and cash equivalents totalled $19.5 million, representing an increase of $4.1 million from March 31, 2016. The increase is attributable to net proceeds from the April 2016 "bought deal" common share offering in the first quarter of the fiscal year 2017 and the exercise of options and warrants together totalling $11.5 million partially offset by cash used to fund operations, investments in facility enhancements and international development together totalling $7.4 million. Investments in facility enhancements were primarily improvements at our Smiths Falls facility including the conversion of growing rooms, in the expansion of cannabis oil extract production capacity and in information technology.
The Audited Consolidated Financial Statements and Management's Discussion and Analysis documents have been filed with SEDAR and are available on www.sedar.com. The basis of financial reporting in the Unaudited Condensed Interim Consolidated Financial Statements and Management's Discussion and Analysis documents has been revised to thousands of Canadian dollars, unless otherwise indicated.
Subsequent Events
Tweed Receives Approval to Begin Export of Medical Cannabis to Germany
On July 25, 2016, the Corporation announced that wholly-owned subsidiary Tweed had received the necessary approvals in Canada and Germany to begin exporting medical cannabis for sale to German patients. Working with MedCann GmbH Pharma and Nutraceuticals ("MedCann"), a privately held pharmaceutical importer and manufacturer, the transfer marks an important milestone for the Company and the first known incidence of dried cannabis being exported from a Canadian licensed producer to a major G7 country.
Canopy Growth Corporation Announces Graduation to TSX
On July 25, 2016, the Company announced that is has received final approval for the listing of the Corporation's common shares (the "Common Shares") on the Toronto Stock Exchange ("TSX"). The Common Shares commenced trading on the TSX effective as of the open of the market on July 26, 2016 under the symbol "CGC". The Corporations shares were delisted from the TSX Venture Exchange prior to the commencement of trading on July 26, 2016.
Bought Deal Financing
On August 24, 2016, the Company announced that it had closed its previously announced short form prospectus offering, on a bought deal basis, including the exercise in full of the underwriters' over-allotment option. A total of 9,453,000 common shares in the capital of the Company were sold at a price of $3.65 per Share, for aggregate gross proceeds of $34,503,450 ("the Offering"). The Offering was underwritten by a syndicate of underwriters co-led by Dundee Securities Ltd. and GMP Securities L.P and including INFOR Financial Inc. and PI Financial Corp.
Regulatory Change
On August 11, 2016, Health Canada announced the new Access to Cannabis for Medical Purposes Regulations (the "ACMPR") which will come into force on August 24, 2016, replacing the MMPR as the regulations governing Canada's medical cannabis program. While the general policy of the ACMPR was disclosed by Health Canada on August 11, 2016, exact regulations will not be available until on or about August 24, 2016. The ACMPR is being implemented as a result of the Federal Court ruling in the case of Allard v. Canada (the "Allard Decision"). In the Allard Decision the Federal Court found the MMPR to be unconstitutional and of no force and effect, but suspended its declaration of invalidity for six months in order to give the government time to respond. As per Health Canada's statement and corresponding fact sheet released on August 11, 2016, the ACMPR will allow Canadians who have been authorized by their health care practitioner, and who are registered with Health Canada, to produce a limited amount of medical marijuana for their own medical purposes, or to designate someone who is registered with Health Canada to produce it for them. Starting materials such as plants or seeds are to be obtained from Licensed Producers only. On August 24, 2016, the government released legislation to enact the policy announcement made on August 11, 2016.
Note 1: The Adjusted Product Contribution is a non-GAAP financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. The Adjusted Product Contribution is reconciled and explained in Management's Discussion & Analysis under "Adjusted Product Contribution (Non-GAAP Measure)", a copy of which has been filed today on www.sedar.com.
Webcast and Conference Call Information
Canopy Growth will host a conference call and audio webcast with Bruce Linton, CEO and Tim Saunders, CFO at 8:30 AM Eastern Time today.
Webcast Information
A live audio webcast will be available at:
http://event.on24.com/r.htm?e=1228175&s=1&k=C0DAE17790A73E74952EDF46ABFED8A0
Calling Information
Toll Free Dial-In Number: 1-888-231-8191
International Dial-In Number (647) 427-7450
Conference ID: 52385525
Replay Information
A replay of the call will be accessible by telephone until 11:59 PM ET on September 19, 2016.
Toll Free Dial-in Number: 1-855-859-2056
Replay Password: 52385525
About Canopy Growth Corporation
Canopy Growth is a world-leading diversified cannabis company, offering diverse brands and curated cannabis strain varieties in dried and oil extract forms. Through its wholly-owned subsidiaries, Tweed, Tweed Farms, and Bedrocan Canada, Canopy Growth operates three state-of-the-art production facilities with over half a million square feet of indoor and greenhouse production capacity. Canopy Growth has established partnerships with leading sector names in Canada and abroad. For more information, www.canopygrowth.com.
Notice Regarding Forward Looking Statements
This news release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth Corporation, Tweed Inc., Tweed Farms Inc. or Bedrocan Canada Inc. to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Examples of such statements include future operational and production capacity, the impact of enhanced infrastructure and production capabilities, and forecasted available product selection. The forward-looking statements included in this news release are made as of the date of this news release and Canopy Growth Corp. does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation. Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.
| Canopy Growth Corporation |
|||||
| Condensed interim consolidated statements of net (loss) income and comprehensive (loss) income for the three-months ended June 30, 2016 and 2015 |
|||||
| (Expressed in CDN $000's except per share amounts) |
|||||
| (Unaudited) |
|||||
| June 30, |
June 30, |
||||
| 2016 |
2015 |
||||
| Revenue |
$ |
6,984 |
$ |
1,710 |
|
| Unrealized gain on changes in fair value of biological assets |
(6,684) |
(5,275) |
|||
| Inventory expensed to cost of sales |
6,654 |
1,492 |
|||
| Production costs |
3,569 |
1,398 |
|||
| Cost of sales (recovery), net of the unrealized gain on changes in fair value of biological assets |
3,539 |
(2,385) |
|||
| Gross margin |
3,445 |
4,095 |
|||
| Sales and marketing |
2,260 |
1,009 |
|||
| Research and development |
403 |
38 |
|||
| General and administration |
2,850 |
1,415 |
|||
| Share of loss in equity investments |
220 |
- |
|||
| Share-based compensation expense |
888 |
372 |
|||
| Depreciation and amortization |
911 |
268 |
|||
| 7,532 |
3,102 |
||||
| (Loss) income from operations |
(4,087) |
993 |
|||
| Interest income (expense), net |
(47) |
19 |
|||
| (Increase) decrease in fair value of acquisiton consideration related liabilities |
(12) |
- |
|||
| (59) |
19 |
||||
| Net (loss) income and comprehensive (loss) income before income taxes |
(4,146) |
1,012 |
|||
| Income tax recovery |
197 |
- |
|||
| Net (loss) income and comprehensive (loss) income after income taxes |
$ |
(3,949) |
$ |
1,012 |
|
| Net (loss) income per share, basic: |
$ |
(0.04) |
$ |
0.02 |
|
| Weighted average number of outstanding common shares, basic: |
103,663,724 |
50,875,433 |
|||
| Net (loss) income per share, diluted: |
$ |
(0.04) |
$ |
0.02 |
|
| Weighted average number of outstanding common shares, diluted: |
103,663,724 |
56,260,530 |
|||
| Canopy Growth Corporation |
|||||||
| Condensed interim consolidated statements of financial position |
|||||||
| (Expressed in CDN $000's) |
|||||||
| (Unaudited) |
|||||||
| June 30, |
March 31, |
||||||
| 2016 |
2016 |
||||||
| Assets |
|||||||
| Current assets |
|||||||
| Cash and cash equivalents |
$ |
19,527 |
$ |
15,397 |
|||
| Restricted short-term investment |
250 |
- |
|||||
| Accounts receivable |
1,410 |
1,110 |
|||||
| HST recoverable |
272 |
376 |
|||||
| Biological assets |
4,049 |
5,321 |
|||||
| Inventory |
24,237 |
22,153 |
|||||
| Prepaid expenses and other assets |
630 |
489 |
|||||
| 50,375 |
44,846 |
||||||
| Property, plant and equipment |
46,119 |
44,581 |
|||||
| Leasehold construction in process |
2,576 |
403 |
|||||
| Restricted investment |
- |
246 |
|||||
| Goodwill |
20,867 |
20,867 |
|||||
| Intangible assets |
31,787 |
31,861 |
|||||
| Other assets |
509 |
557 |
|||||
| $ |
152,233 |
$ |
143,361 |
||||
| Liabilities |
|||||||
| Current liabilities |
|||||||
| Accounts payable and accrued liabilities |
$ |
6,785 |
$ |
6,107 |
|||
| Deferred revenue |
216 |
533 |
|||||
| Current portion of long-term debt |
639 |
553 |
|||||
| 7,640 |
7,193 |
||||||
| Long-term debt |
3,489 |
3,469 |
|||||
| Acquisition consideration related liabilities |
1,270 |
1,258 |
|||||
| Deferred tax liability |
7,216 |
7,413 |
|||||
| Other long-term liabilities |
237 |
243 |
|||||
| 19,852 |
19,576 |
||||||
| Shareholders' equity |
|||||||
| Share capital |
143,184 |
131,080 |
|||||
| Share-based reserve |
6,921 |
5,804 |
|||||
| Warrants |
- |
676 |
|||||
| Deficit |
(17,724) |
(13,775) |
|||||
| 132,381 |
123,785 |
||||||
| $ |
152,233 |
$ |
143,361 |
||||
| Canopy Growth Corporation |
||||||
| Condensed interim consolidated statements of cash flows for the three-months ended June 30, 2016 and 2015 |
||||||
| (Expressed in CDN $000's) |
||||||
| (Unaudited) |
||||||
| June 30, |
June 30, |
|||||
| 2016 |
2015 |
|||||
| Operating |
||||||
| Net income (loss) |
$ |
(3,949) |
1,012 |
|||
| Items not affecting cash: |
||||||
| Depreciation of property, plant and equipment |
837 |
265 |
||||
| Amortization of intangible assets |
74 |
3 |
||||
| Share of loss in equity investments |
220 |
- |
||||
| Unrealized gain on change in fair value of biological assets |
(6,684) |
(5,275) |
||||
| Share-based compensation |
975 |
372 |
||||
| Income tax recovery |
(197) |
- |
||||
| Decrease in fair value of acquisition consideration related liabilities |
12 |
- |
||||
| Changes in non-cash operating working capital items |
4,405 |
326 |
||||
| Net cash used in operating activities |
(3,766) |
(3,297) |
||||
| Financing |
||||||
| Proceeds from issuance of common shares |
11,506 |
- |
||||
| Proceeds from exercise of stock options |
659 |
- |
||||
| Proceeds from exercise of warrants |
126 |
126 |
||||
| Payment of share issue costs |
(790) |
(189) |
||||
| Issuance (repayment) of long-term debt |
260 |
- |
||||
| Increase in other long-term liabilities |
(6) |
27 |
||||
| Net cash provided by (used in) financing activities |
11,602 |
(98) |
||||
| Investing |
||||||
| Purchases of property, plant and equipment |
(2,531) |
(1,410) |
||||
| Purchases of leasehold construction in process |
(1,175) |
(1,186) |
||||
| Purchases of restricted investments |
- |
(286) |
||||
| Net cash used in investing activities |
(3,706) |
(2,882) |
||||
| Net cash inflow (outflow) |
4,130 |
(6,277) |
||||
| Cash and cash equivalents, beginning of period |
15,397 |
21,446 |
||||
| Cash and cash equivalents, end of period |
$ |
19,527 |
$ |
15,169 |
||
| Unaudited Non-GAAP Measure (In CDN$000's, except gram amounts) |
Three Months Ended June 30, 2016 |
Three Months Ended June 30, 2015 |
||||
| Adjusted Product Contribution1 |
||||||
| Weighed average cost per gram |
$ |
2.66 |
$ |
3.16 |
||
| Grams sold in the period |
984,334 |
215,929 |
||||
| Revenue |
$ |
6,984 |
$ |
1,710 |
||
| Adjusted cost of sales2 |
(2,618) |
(682) |
||||
| Adjusted Product Contribution |
$ |
4,366 |
$ |
1,028 |
||
| Adjusted Product Contribution percentage of sales |
62.5% |
60.1% |
||||
| As compared to the Gross Margin per IFRS: |
||||||
| Gross margin |
$ |
3,445 |
$ |
4,095 |
||
| Gross margin percentage of sales |
49.3% |
239.5% |
||||
| Notes: |
|||||
| 1 The Adjusted Product Contribution removes the fair value measurements required under IFRS and recognizes the cost of sales based on the weighted average cost per gram to produce and sell product in the period. |
|||||
| 2 Based on the weighted average of cost per gram from seed to sale of $2.66 per gram in the first quarter. |
|||||
SOURCE Canopy Growth Corporation
Image with caption: "Quarterly Revenue - Fiscal 2016 & 2017 (CNW Group/Canopy Growth Corporation)". Image available at: http://photos.newswire.ca/images/download/20160829_C2196_PHOTO_EN_760942.jpg
Image with caption: "Patients At Quarter's End (CNW Group/Canopy Growth Corporation)". Image available at: http://photos.newswire.ca/images/download/20160829_C2196_PHOTO_EN_760940.jpg
Image with caption: "Grams And Gram Equivalents Sold (CNW Group/Canopy Growth Corporation)". Image available at: http://photos.newswire.ca/images/download/20160829_C2196_PHOTO_EN_760938.jpg
Tyler Burns, Investor Relations, Canopy Growth Corporation, [email protected], 1-855-558-9333 ex 122; Director: Bruce Linton, [email protected], [email protected]
Share this article